{'52WeekChange': 'Infinity',
 'SandP52WeekChange': None,
 'address1': '480 Arsenal Way',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 12.9,
 'askSize': 800,
 'averageDailyVolume10Day': 74325,
 'averageVolume': 171957,
 'averageVolume10days': 74325,
 'beta': None,
 'beta3Year': None,
 'bid': 10.6,
 'bidSize': 800,
 'bookValue': None,
 'category': None,
 'circulatingSupply': None,
 'city': 'Watertown',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.9,
 'dayLow': 11.78,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -16.672,
 'enterpriseToRevenue': None,
 'enterpriseValue': 285352928,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.462,
 'fiftyTwoWeekHigh': 22,
 'fiftyTwoWeekLow': 10.44,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 4903579,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fullTimeEmployees': 34,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.01386,
 'heldPercentInstitutions': 0.03427,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/lyratherapeutics.com',
 'longBusinessSummary': 'Lyra Therapeutics, Inc., a clinical-stage '
                        'therapeutics company, focuses on the development and '
                        'commercialization of novel integrated drug and '
                        'delivery solutions for the localized treatment of '
                        'patients with ear, nose, and throat diseases. The '
                        "company's XTreo technology platform is designed to "
                        'deliver medicines directly to the affected tissue for '
                        'sustained periods with a single administration. Its '
                        'product candidates include LYR-210 and LYR-220, which '
                        'are bioresorbable polymeric matrices for the '
                        'treatment of chronic rhinosinusitis. The company was '
                        'formerly known as 480 Biomedical, Inc. and changed '
                        'its name to Lyra Therapeutics, Inc. in July 2018. '
                        'Lyra Therapeutics, Inc. was founded in 2005 and is '
                        'headquartered in Watertown, Massachusetts.',
 'longName': 'Lyra Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 163496192,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_142648423',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -17270000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.39,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 1.15,
 'phone': '617 393 4600',
 'previousClose': 12.17,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.9,
 'regularMarketDayLow': 11.78,
 'regularMarketOpen': 12.39,
 'regularMarketPreviousClose': 12.17,
 'regularMarketPrice': 12.39,
 'regularMarketVolume': 72055,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 12924600,
 'sharesPercentSharesOut': 0.0349,
 'sharesShort': 451273,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 60704,
 'shortName': 'Lyra Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0799,
 'shortRatio': 2.4,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'LYRA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': None,
 'twoHundredDayAverage': 13.740848,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'e0a4f15e-34ef-3087-b120-b47efafe701f',
 'volume': 72055,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.lyratherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02472'}